Clinical Trials

Is HilleVax's Norovirus Vaccine Viable for Adult Populations?
Research & Development Is HilleVax's Norovirus Vaccine Viable for Adult Populations?

HilleVax, a biotechnological firm previously in the spotlight for its experimental Norovirus vaccine, HIL-214, has made headlines again. After an extensive and ultimately disappointing Phase 2b trial in infants, the company is now strategizing a new target demographic: adults. Given the intricate

Immix Biopharma Begins U.S. Dosing in NXC-201 AL Amyloidosis CAR-T Trial
Research & Development Immix Biopharma Begins U.S. Dosing in NXC-201 AL Amyloidosis CAR-T Trial

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, has reached a pivotal milestone by dosing its first patient in the U.S. for the NEXICART-2 clinical trial. This significant achievement aims to treat relapsed/refractory AL Amyloidosis using CAR-T cell therapy, known as NXC-201.

How is Clinical Trial Outsourcing Transforming Drug Development?
Research & Development How is Clinical Trial Outsourcing Transforming Drug Development?

Clinical trial outsourcing has fundamentally transformed the landscape of drug development, allowing pharmaceutical companies to streamline operations, reduce costs, and accelerate the path to market. This paradigm shift is driven by several converging factors, including the rapid growth in

Emerging Innovations Propel CAR-T Therapy to 2033 Market Expansion
Research & Development Emerging Innovations Propel CAR-T Therapy to 2033 Market Expansion

The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown i

Can NK Cell Therapy Revolutionize Autoimmune Disease Treatment?
Research & Development Can NK Cell Therapy Revolutionize Autoimmune Disease Treatment?

Natural Killer (NK) cell therapy, once a promising beacon for cancer treatment, is now being repositioned as a potential game-changer in the management of autoimmune diseases. Biotech companies, like Artiva Biotherapeutics, are shifting their focus to explore the untapped potential of NK cell

Can GTB-3650 Revolutionize CD33+ Leukemia Treatment with NK Cell Engagers?
Research & Development Can GTB-3650 Revolutionize CD33+ Leukemia Treatment with NK Cell Engagers?

In a significant achievement for GT Biopharma, Inc., the FDA has granted clearance for the company's Investigational New Drug (IND) application for GTB-3650, a novel NK cell engager aimed at treating CD33+ leukemia. This regulatory milestone allows the clinical-stage immuno-oncology company to

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later